Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?

about

Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?

Item

http://www.wikidata.org/entity/Q58766423

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Weekly versus 3-weekly paclita ...... adjuvant chemotherapy regimen?

@en

Weekly versus 3-weekly paclita ...... adjuvant chemotherapy regimen?

@nl

type

Item

label

Weekly versus 3-weekly paclita ...... adjuvant chemotherapy regimen?

@en

Weekly versus 3-weekly paclita ...... adjuvant chemotherapy regimen?

@nl

prefLabel

Weekly versus 3-weekly paclita ...... adjuvant chemotherapy regimen?

@en

Weekly versus 3-weekly paclita ...... adjuvant chemotherapy regimen?

@nl

P1476

Weekly versus 3-weekly paclita ...... adjuvant chemotherapy regimen?

@en

P2093

David Sp Tan

http://www.w3.org/2001/XMLSchema#string

Matilda X Lee

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 4.0 License

P2860

Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

Ovarian cancer: pathology, biology, and disease models

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

A phase 3 trial of bevacizumab in ovarian cancer.

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

Weekly administration of paclitaxel: theoretical and clinical basis.

P304

e96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.3802/JGO.2018.29.E96

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30207104

http://www.w3.org/2001/XMLSchema#string

P921

ovarian neoplasm

ovarian cancer

organometallic compound

hydrocarbon

chemotherapy

P932

6189442

http://www.w3.org/2001/XMLSchema#string